Pregnancies During and After Trastuzumab and/or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Analysis From the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) Trials

Cancer - United States
doi 10.1002/cncr.31784
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis

Scientific Reports
Multidisciplinary
2016English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Cancer
Cancer ResearchOncology
2019English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues

Korean Journal of Clinical Oncology
2015English

Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2014English

Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy